ArticleJournal of translational medicine2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Article
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Adding recombinant AAVs to the cancer therapeutics mix.Molecular therapy oncolytics · 2022Review
- An overview of multiplexed analyses of CAR T-cell therapies: insights and potential.Expert review of proteomics · 2021Article
- Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.Cell reports · 2019Article
- T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.Critical reviews in immunology · 2019Review
- Single-cell analysis tools for drug discovery and development.Nature reviews. Drug discovery · 2016Review
- Cellular Therapies in Systemic Sclerosis: Recent Progress.Current rheumatology reports · 2016Review
- In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study.OncoTargets and therapy · 2016Article
- T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response.Cancer immunology, immunotherapy : CII · 2015Article
- Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.Journal of immunology research · 2015Review
- Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Frontiers in immunology · 2015Review
- Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies.Clinical & translational immunology · 2014Review
- Review
- Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.PloS one · 2014Article
- Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors.Frontiers in oncology · 2013Review
- Review
- Cell-based immunotherapy against gliomas: from bench to bedside.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.Journal of hematology & oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.